Empiric Intravenous Acyclovir for Suspected HSV Encephalitis in Infants

Indications and Clinical Decision‑Making

• Intravenous acyclovir should be initiated immediately (500 mg/m² every 8 h) when clinical suspicion of HSV encephalitis exists, rather than waiting for laboratory confirmation. 1
• Distinguish simple febrile seizures from viral encephalitis: acyclovir is mandatory for encephalitis but not indicated for isolated febrile seizures. 1, 2
• A generalized tonic seizure lasting ≈ 10 minutes is atypically long for a febrile seizure (< 5 minutes) and raises concern for encephalitis. 1
• Empiric acyclovir should be started within 6 hours of admission if any of the following are present: altered consciousness, confusion, or behavioral changes beyond the post‑ictal state; anticipated delay in lumbar puncture or imaging results; or rapid clinical deterioration/severe illness. 1, 2, 3
• Untreated HSV encephalitis carries ≈ 70 % mortality, whereas treatment reduces mortality to 20‑30 %; delays beyond 48 hours markedly worsen outcomes. 1, 2

Dosing, Duration, and Renal Adjustment

• Recommended dose for children aged 3 months–12 years: 500 mg/m² IV every 8 hours (≈ 20 mg/kg per dose). 1, 2
• Minimum treatment course is 21 days; shorter courses (< 21 days) are associated with a 26‑29 % relapse rate in this age group. 1, 3
• Dose reduction is required in the presence of renal impairment. 1

Diagnostic Work‑up While Treating

• Perform lumbar puncture immediately unless contraindicated by signs of raised intracranial pressure; CSF HSV PCR remains positive for 7‑10 days after acyclovir initiation, allowing delayed sampling to confirm diagnosis. 1, 3

Safety Monitoring and Adverse Effects

• Oral acyclovir is ineffective for CNS infections and should not be used. 1, 3
• Nephrotoxicity occurs in up to 20 % of patients after 4 days of IV therapy; ensure adequate IV hydration and monitor renal function (creatinine, urine output) regularly. 1, 2
• Rare but serious adverse events include hepatitis, bone‑marrow suppression, and encephalopathy. 1, 3

Treatment Duration and Stopping Criteria

• Continue IV acyclovir for 14‑21 days (minimum 21 days in children 3 months–12 years); obtain repeat lumbar puncture with HSV PCR.
• If PCR remains positive, extend therapy and repeat PCR weekly until negative. If PCR is negative and an alternative diagnosis is established, acyclovir may be discontinued. 1, 3

Overall Clinical Judgment

• The decision to start acyclovir hinges on identifying encephalitic features beyond a simple febrile seizure; the prolonged 10‑minute seizure and the need to rule out a high‑mortality, treatable HSV encephalitis support empiric therapy while awaiting confirmatory testing. 1, 2

Management of Aseptic Meningitis and Encephalitis

Introduction to Aseptic Meningitis

• The British Infection Association states that there is no evidence supporting the use of acyclovir or valaciclovir for herpes meningitis (HSV or VZV) 4
• Aseptic meningitis is most commonly caused by viruses, with no proven benefit from antiviral treatments for most cases 4
• Treatment should focus on supportive care with analgesia and fluids as necessary 4

Diagnostic Approach and Treatment of Encephalitis

• Intravenous acyclovir is indicated for viral encephalitis, particularly when HSV or VZV is suspected 5, 4
• For HSV encephalitis, acyclovir should be administered at 10 mg/kg intravenously every 8 hours in adults with normal renal function for 14-21 days 5
• Early initiation of acyclovir therapy for HSV encephalitis is critical, as mortality decreases significantly when started within 4 days of symptom onset 5
• Encephalitis involves altered mental status, confusion, behavioral changes, seizures, or focal neurological deficits 6

Diagnostic Workup

• Lumbar puncture is essential: check cell count, protein, glucose, and perform PCR for HSV and other viruses 6, 7
• MRI of the brain is more sensitive than CT for detecting encephalitis-related changes 8
• EEG may help identify subclinical seizures in encephalitis cases 6

Potential Pitfalls in Management

• Failing to distinguish between viral meningitis (where acyclovir is not indicated) and HSV encephalitis (where intravenous acyclovir is essential) can lead to inappropriate treatment 4
• Unnecessary use of acyclovir for aseptic meningitis can lead to adverse effects including nephropathy, which occurs in up to 20% of patients after 4 days of IV therapy 8
• Empirical use of antimicrobial and antiviral agents can prematurely halt the diagnostic pathway because clinicians feel falsely reassured, delaying identification of other etiologies 8

Management of HSV Meningitis in Immunocompetent Adults

Diagnosis and Treatment Decision

• In immunocompetent adults with laboratory‑confirmed HSV meningitis without encephalitic features (e.g., normal mental status, isolated headache, photophobia, fever, meningismus), supportive care alone is recommended and acyclovir is not indicated. The UK Joint Specialist Societies guideline states that these patients recover completely without neurologic sequelae. Strength of evidence: expert consensus / lack of randomized data. 9

• The presence of any encephalitic signs—such as personality or behavioral changes, confusion, cognitive impairment, seizures, focal neurological deficits, or altered level of consciousness—requires immediate escalation to full‑dose intravenous acyclovir. Strength of evidence: expert consensus. 10

Treatment Recommendations

• Do not initiate acyclovir for a pure meningitis syndrome in immunocompetent adults (headache, photophobia, fever, meningismus, and normal mental status). Strength of evidence: expert consensus. 9

• Do not treat pure HSV meningitis in immunocompetent adults with antiviral agents; the potential drug toxicity and prolonged hospitalization outweigh any unproven benefit. Strength of evidence: expert consensus. 9

Prophylaxis for Recurrent HSV‑2 (Mollaret’s) Meningitis

• Prophylactic valacyclovir 500 mg twice daily is not recommended for preventing recurrences of recurrent HSV‑2 meningitis. A placebo‑controlled randomized trial showed no reduction in recurrence rates and a higher relapse rate after discontinuation. Strength of evidence: randomized controlled trial. 9

Guideline Comparison (UK vs. US)

• The UK Joint Specialist Societies explicitly recommend no antiviral treatment for immunocompetent HSV meningitis due to the absence of supporting evidence and excellent outcomes with supportive care alone. Strength of evidence: expert consensus. 9
• In contrast, many US‑based guidelines suggest treatment despite acknowledging the same evidence gap, reflecting a divergence in practice patterns. Strength of evidence: expert consensus (US guidance). 10